Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
BioMAV
1 other identifier
observational
300
1 country
1
Brief Summary
The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 11, 2018
CompletedFirst Posted
Study publicly available on registry
September 19, 2018
CompletedStudy Start
First participant enrolled
November 20, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 19, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 19, 2028
June 25, 2025
June 1, 2025
10 years
September 11, 2018
June 19, 2025
Conditions
Outcome Measures
Primary Outcomes (4)
Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic
associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome
6 months
Associaton between dosage of platelet and the arteriovenous malformation pronostic
Dosage of platelet in blood samples and correlation with clinical outcome
6 months
Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic
Dosage of neutrophilic in blood samples and correlation with clinical outcome
6 months
Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic
Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome
6 months
Eligibility Criteria
Patient with a cerebral arterioveinus malformation for which an intervention (endovascular treatment or surgery) or only clinical monitoring is planned
You may qualify if:
- Patient over 18 years old
- Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring
- Express consent to participate in the study
- And
- children
- Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority
You may not qualify if:
- Patient benefiting from a legal protection measure
- Pregnant or breast feeding woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fondation Ophtalmologique Rotschild
Paris, 75019, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 11, 2018
First Posted
September 19, 2018
Study Start
November 20, 2018
Primary Completion (Estimated)
November 19, 2028
Study Completion (Estimated)
November 19, 2028
Last Updated
June 25, 2025
Record last verified: 2025-06